After gaining approval for T2DM, SGLT2 inhibitors were also approved for chronic kidney disease and heart failure in the non-diabetic population due to their beneficial effects on the cardiovascular and renal systems [5,25]. This evidence concerns the gene SLC5A2 and chronic kidney disease.